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RABIATUL ADAWIYAH RAZALI, ABID NORDIN, AMINUDDIN BIN SAIM & ISA NAINA-MOHAMED
ABSTRACT
Ficus carica, a native plant to the Middle East and Western Asia, is of high value in folk medicine. The therapeutic potential 
of Ficus carica has led to the extensive studies in recent years, focusing on evaluating and validating its pharmacological 
effect. The present systematic review summarizes the effectiveness of Ficus carica on promoting bone health focusing on 
osteoporosis and rheumatoid arthritis via mineral contents and RANKL pathway. The search was done with Medline via 
Ebscohost, Scopus and Google Scholar databases to obtain relevant articles published between 1946 and December 
2016. The main inclusion criteria were research articles published in English that reported effect of Ficus carica on 
bone health. The literature search returned 716 potentially relevant articles, whereby 5 met the inclusion criteria. This 
systematic review concludes Ficus carica plays an important role in the promotion of bone health and can be a potential 
pharmaceutical product in the future.
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ABSTRAK
Ficus carica ialah tumbuhan asli di Timur Tengah dan Asia Barat mempunyai kepentingan dalam perubatan tradisi. Potensi 
terapeutik Ficus carica telah membawa kepada kajian mendalam tertumpu kepada pengesahan kesan farmakologinya. 
Kajian sistematik ini mendalami keberkesanan Ficus carica dalam membantu kesihatan tulang yang memfokus kepada 
penyakit osteoporosis dan ‘reumatoid artritis’ melalui kandungan mineralnya dan laluan RANKL. Carian makalah telah 
dibuat menggunakan pangkalan data Medline melalui Ebscohost, Scopus dan Google Scholar untuk mendapatkan 
makalah berkaitan yang diterbitkan antara 1946 dan December 2016. Kriteria rangkuman utama untuk pemilihan 
makalah adalah penerbitan dalam Bahasa Inggeris yang melaporkan kesan Ficus carica kepada kesihatan tulang. Carian 
makalah menghasilkan 716 makalah yang berpotensi dengan 5 makalah menepati kriteria rangkuman. Kesimpulan 
kajian sistematik ini membuktikan bahawa Ficus carica memainkan peranan penting dalam membantu meningkatkan 
kesihatan tulang dan boleh dijadikan sebagai produk farmaseutik yang berpotensi pada masa hadapan.
Kata kunci: Ficus carica; laluan RANKL; osteoporosis; reumatoid artritis; tulang 
INTRODUCTION
Ficus carica or commonly known as fig is a flowering plant 
belongs to the Moraceae family. It is one of the largest 
genera of angiosperms with more than 800 species of 
trees, epiphytes, and shrubs identified in the tropical and 
sub-tropical regions worldwide (Vinson 1999). It is known 
to be one of the earliest fruits cultivated in history (Singh 
et al. 2011). Ficus carica has been extensively studied for 
medicinal uses, which justifies its potential therapeutic 
value (Khairuddin et al. 2017; Mawa et al. 2013; 
Moniruzzaman et al. 2017). A report done by Gilani et al. 
(2008) showed that the fruit, root and leaves of Ficus carica 
are used in complementary medicine in different disorders 
such as spasm, respiratory disorders, inflammatory, gastro-
intestinal disorders and cardiovascular disorders.
 The therapeutic potential of Ficus carica has led to the 
extensive studies in recent years, focusing on evaluating 
and validating its pharmacological effect. Ficus carica 
has been reported to possess antioxidant activity (Feng & 
Ma 2010; Prabavathy & Nachiyar 2011), anti-angiogenic 
activity, anticancer activity (Rubnov et al. 2001), 
antibacterial activity (Aref et al. 2010; Jeong et al. 2009; 
Mavlonov et al. 2008), cytotoxicity activity (Khodarahmi 
et al. 2011), anticonstipation activity (Lee et al. 2012), 
hepatoprotective activity (Gond et al. 2008; Mohan 
et al. 2007), antihelmintic activity (Amol et al. 2010; 
Chandrashekhar et al. 2008), anti-inflammatory activity 
(Patil et al. 2011), antimutagenic activity (Agabeĭli et al. 
2005), antipyretic activity (Patil et al. 2010), antispasmodic 
activity (Gilani et al. 2008), antiplatelet activity (Gilani 
et al. 2008), hypoglycemic activity (El- Shobaki et al. 
2010; Perez et al. 1996), hypolipidimic activity (Asadi et 
al. 2006), antiviral activity (Lazreg Aref et al. 2011) and 
immunostimulant activity (Patil et al. 2010). 
 Fruits such as olive (Chin & Ima-Nirwana 2016) and 
pomegranate (Shuid & Mohamed 2013) as an alternative 
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dietary supplementation for osteoporosis have been 
suggested for individual who preferred vegan diet or 
those who have medical condition that prevents them from 
consuming dairy or meat product such as milk allergy. 
 Mineral content of fig has been reported to closely 
resemble that of human milk, with iron being the most 
important. The iron content in Ficus carica is also said to 
be 50% as much as that of beef liver (Lydia 2009). In plant 
eating bird, Ficus carica has been reported to be the choice 
for dietary source of calcium by O’Brien et al. (1998). 
Together, their findings suggested the potential of Ficus 
carica as an alternative dietary supplement for prevention 
of osteoporosis. 
 Bone problem such as bone loss, osteoporosis and 
rheumatoid arthritis are a global health problem. Aging 
can reduce bone mineral density (BMD), eventually leading 
to osteoporosis. Dairy products with high level of calcium 
are recommended to be consumed in order to promote and 
maintain BMD level, especially in the elderly. Apart from 
being nutritional source of minerals, Ficus carica has also 
been reported to modulate bone remodelling (Choi et al. 
2011; Park et al. 2009). The mechanism of bone remodeling 
is composed of a balance between bone resorption phase 
regulated by osteoclast and bone formation phase regulated 
by osteoblast (Liu et al. 2010; Raggatt et al. 2010). The 
imbalance of bone remodeling process caused by an 
excessive differentiation of osteoclast cells has been 
previously reported, that can lead to bone lytic diseases, 
such as osteoporosis and rheumatoid arthritis (Park et al. 
2008).
 The activation of osteoclasts is known to be regulated 
by two cytokines; receptor activator of nuclear factor-κβ 
ligand (RANKL) and macrophage colony-stimulation factor 
(M-CSF). The binding of RANKL to its receptor RANK on the 
surface of osteoclast, leads to the activation of TNF receptor-
associated factor 6 (TRAF6), which is linked to nuclear 
factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) via mitogen-activated protein kinases (MAPKs). 
RANKL and M-CSF are proteins secreted by osteoblasts and 
is important for the formation of osteoclast and regulation 
of its activity (Boyce & Xing 2008).
 Studies led by Choi et al. (2011) and Park et al. (2009), 
respectively, have showed that Ficus carica can act as a 
potent inhibitor of osteoclastogenesis in receptor activator 
of nuclear factor kappa-B ligand (RANKL) pathway and 
regulates expression of osteoblast specific genes such as 
bone morphogenetic protein 2 (BMP-2), osteoprotegerin 
(OPG) and osteocalcin (OCN). The importance of RANKL 
signaling mechanism in bone remodelling is well 
established (Liu et al. 2010; Raggatt et al. 2010). Both 
studies suggested that Ficus carica may potentially provide 
a novel therapy for bone disorder such as osteoporosis 
(Choi et al. 2011; Park et al. 2009).
 In this review, studies reporting the beneficial effect of 
Ficus carica on bone health via its high mineral contents 




A systematic review of the literature was conducted to 
identify relevant studies reporting the effects of Ficus 
carica on bone health. Two databases were searched in 
regard to this, Medline via Ebscohost and Scopus (both 
published between 1946 and December 2016) and Google 
Scholar (no limitation in search). The search strategy 
involved a combination of the following sets of key words; 
Ficus carica AND osteo* OR rheum* OR bone*.
INCLUSION AND EXCLUSION CRITERIA
The results were limited only to the studies published in 
English language due to limited resources for translation 
services. Primary literature with research focus on Ficus 
carica effects on bone health was included. Review articles, 
news, letter, editorials or case studies were excluded from 
the review. Study not related to Ficus carica effects on 
bone health were removed.
DATA EXTRACTION AND MANAGEMENT
Articles were screened prior to their inclusion in this 
review. Titles and abstracts were screened first to ensure 
inclusion and exclusion criteria were adhered. In the final 
phase, the remaining papers were read thoroughly and the 
data extracted. The following data were recorded from 
the studies: the types of study; aims of study; subject or 
sample; methods; result; and remarks or conclusion. All 
the data extraction and management were re-evaluated by 
two independent reviewers to validate the data integrity.
RESULTS
LITERATURE SEARCH
The literature identified several relevant articles. All the 
articles were assessed for inclusion or exclusion based 
on the title and abstract. The search yielded 716 articles, 
of which 5 articles met the inclusion criteria. All data 
were extracted directly from the articles. A flow chart 
of the selection and paper process including reasons for 
exclusion is shown in Figure 1. Further details on each 
study regarding methodological and outcome aspects were 
summarized in Table 1.
EVALUATION OF MAJOR MINERAL CONTENTS OF FICUS 
CARICA CRUCIAL FOR BONE HEALTH
Three studies were included in this review to evaluate 
the mineral contents of Ficus carica that is crucial for 
bone health (Khan et al. 2011; Sadia et al. 2014; Soni et 
al. 2014). Khan et al. (2011) was the earliest to conduct 
physicochemical profiling of Ficus carica (Sadia et al. 
2014). Their findings showed that their fig samples contain 
high amount of potassium (K) at 382.4-611.5 mg/100 g. 
This is followed by magnesium (Mg) at 110.50-202.40 
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mg/100 g, Calcium (Ca) 78.72-132.80 mg/100 g and 
phosphorous (P) at 31.91-76.96 mg/100 g (Khan et al. 
2011). They suggested that the minerals found in Ficus 
carica fruit are essential for bone growth and maintenance.
 Sadia et al. (2014) has led a study to evaluate the 
physicochemical characteristics of a few species of 
underutilized figs and mulberries. It showed that the dried 
figs extract contains higher concentration of trace elements 
such as potassium (K), magnesium (Mg), calcium (Ca), 
phosphorus (P) and Iron (Fe) [31]. Accordingly, Ficus 
carica was reported to have the highest level of Ca ((10.94 
± 2.75) mg/g dry weight) among all the fruits tested (Sadia 
et al. 2014).
 This is in agreement to another study led by Soni et 
al. (2014) that reported dried fig to be a very good source 
of minerals like Strontium (Sr), Ca, Mg, P and Fe (Soni 
et al. 2014). They found that Strontium has the highest 
amount in fig (saturated) while the level of Ca, Mg, P 
and Fe to be relatively high at 1545.46, 679.04, 365.75 
and 29.49 ppm, respectively. Strontium and calcium in 
dried fig has been found to contribute towards good bone 
health (Soni et al. 2014). In terms of nutritional profile, 
fig have carbohydrates as a major component (73.50%), 
high energy value (317.78 kcal), very low amount of fat 
(0.56%), moderate amount of protein (4.67%), dietary fiber 
content (3.68%), found to contain moisture (16.63%) and 
high ash content (4.65%) (Soni et al. 2014).
EFFECT OF FICUS CARICA ON MOLECULAR                
MECHANISM OF BONE HEALTH
Studies led by Choi et al. (2011) and Park et al. (2009) 
have successfully linked Ficus carica to the molecular 
mechanism of bone formation via the RANKL signaling. In 
the first study, Choi et al. (2011) tested the effect of four 
types of long chain polyunsaturated fatty acids (PUFAs) 
from Ficus carica, namely E-DHA, DHA, EDA (cis-11, 
14-eicosadienoic acid) and EPA on the osteogenesis 
parameters of RAW264.7 murine macrophages and 
preosteoblastic MC3T3-E1 cells.
 In terms of RAW 264.7 cells, E-DHA was found to 
be a much more potent inhibitor of RANKL-induced 
osteoclastogenesis (Choi et al. 2011). TRAP staining showed 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































that the E-DHA decreased the maturation of preosteoclast 
cells most significantly and reduced the TRAP-positive 
multinucleated cells in RAW264.7 cells (Choi et al. 
2011). E-DHA showed no effect on the RAW264.7 cells 
growth rate evaluated through MTT assay after 24 h 
treatment (Choi et al. 2011). Western blot results showed 
that the E-DHA significantly reduced the expression of 
c-Jun NH2-terminal kinases (JNK) (Choi et al. 2011). 
In contrast, the extracellular signal-regulated kinase 
(ERK), p38 mitogen-activated protein kinases (p38) and 
protein kinase B (Akt) were not modulated. Treatment 
of E-DHA in RAW264.7 cells also significantly reduced 
the expression of IkappaB kinase (IκB) and suppressed 
c-Fos and NFATc1 expression. In addition, the increased 
RANKL-induced level of c-fos mRNA was reversed by 
E-DHA in a concentration-dependent manner. Finally, the 
mRNA expression of MMP-9, TRAP and c-fms was also 
suppressed following the treatment of E-DHA. Overall, 
the data suggested the inhibition of osteoclastogenesis in 
RAW264.7 cells by E-DHA (Choi et al. 2011). Treatment of 
DHA on preosteoblastic MC3T3-E1 cells has been shown 
to promote the highest ALP activity in vitro. However, after 
treatment of E-DHA in preosteoblastic MC3T3-E1 cells, 
osteoclastogenesis was inhibited. RT-PCR results showed 
that osteogenic markers such as BMP2 was increased 
significantly by DHA and EDA but decreased by E- DHA and 
EPA in preosteoblastic MC3T3-E1 cells. Expression of OCN 
was induced slowly by E-DHA compared to other PUFAs. 
OPG expression was consistently induced by E-DHA and 
cis-11, 14-eicosadienoic acid not by DHA and EPA (Choi 
et al. 2011).
 An earlier study done by Park et al. (2009) was 
conducted to assess the effects of the hexane soluble 
fraction of Ficus carica leaf (HF6-FC) on RANKL-induced 
osteoclastogenesis in murine monocytes/macrophage 
RAW264.7 cells and bone marrow-derived macrophages 
(BMMs). In this study, they determined eight types of Ficus 
carica fractions (HF1-HF8), but only HF6-FC was the most 
active for all the parameters.
 They showed that the n-hexane soluble fraction of 
HF6-FC exhibited the strongest anti-osteoclastogenic 
effect. They optimized the extraction method and 
identified components of HF6-FC which are octadecane, 
pentadecane, hexadecane, heptadecane, octadecane, 
2H-1-benzopyran-2-one, nonadecane, hexadecanoic, acid 
methyl ester, octadecanoic acid methyl este, tridecane, 
tetradecane, eicosane, 9,12,-octadecadienoic acid 
methylester and 8-octadecenoic acid (Park et al. 2009).
 Their sample of bone marrow-derived macrophages 
(BMMs) was obtained from mice tibia and femur bone 
marrow and MTT assay was performed to evaluate the 
effect of HF6- FC on the cell growth rate of RAW264.7 and 
BMMs at the various concentrations. The MTT showed that 
the HF6-FC did not adversely affect both cells. Osteoclast 
cells derived from BMM were successfully differentiated 
and cultured in medium containing M-CSF (30 ng/
mL) and RANKL (200 ng/mL). The effect of HF6-FC on 
osteoclastogenesis in murine monocyte/macrophage RAW 
264.7 cells was evaluated via TRAP staining. Treatment of 
HF6-FC on both cells showed a reduction in the numbers 
of TRAP-positive multinucleated osteoclasts indicating 
inhibited osteoclast differentiation in a concentration-
dependent manner (Park et al. 2009). Western blot analysis 
showed that the HF6-FC increased the ERK activity of RAW 
264.7 cells. In contrast, the HF6-FC inhibited the RANKL-
induced p38 kinase activation by significantly reducing the 
level of phosphorylated IκB-α protein of RAW 264.7 cells. 
These suggested that the HF6-FC significantly suppressed 
the level of phosphorylated p65 and the NF-κB induction 
by RANKL in the RAW 264.7 cells. Reverse transcription-
polymerase chain reaction analysis was performed to 
examine the effects of HF6-FC on expression of c-Fos 
and NFATc1 in the RAW 264.7 cells. The result showed 
that HF6-FC significantly suppresses expression of c-Fos 
and NFATc1 in the RAW 264.7 cells (Park et al. 2009).
DISCUSSION
In the present review, major mineral contents of Ficus 
carica, namely potassium (K), magnesium (Mg), calcium 
(Ca), phosphorus (P) and Strontium (Sr) were found 
to be crucial for strong bone development (Khan et al. 
2011; Sadia et al. 2014; Soni et al. 2014). Calcium and 
magnesium is a major component in bone and tooth 
development (Brody & Bender 1994; Reid et al. 1993; 
Rude et al. 2004). Potassium is a blood pressure controlling 
mineral and reported calcium-potassium may also 
neutralize increased urinary calcium loss and helping to 
prevent bones from thinning out at a fast rate (Cozzolino 
et al. 2001).
 Interestingly, Strontium has been shown to improve 
bone health (Marie 2005; Reginster et al. 2007). Clinical 
studies done by Reginster et al. (2007) reported the effect 
of Strontium ranelate (PROTELOS®) was found to reduce 
vertebral and non-vertebral fractures in osteoporosis 
subjects. Strontium ranelate (PROTELOS®) is an oral 
drug for postmenopausal osteoporosis, has been reported to 
decrease bone resorption and to stimulate bone formation. 
Moreover, their finding showed that the figs is a promising 
source of protein, carbohydrate, fibers and vitamins, with 
high energy values.
 Moverover, our sytematic review on molecular 
evaluation of Ficus carica showed that studies done by 
Choi et al. (2011) and Park et al. (2009) were focused 
on the effect of Ficus carica extract on RANKL signalling 
pathway which is very important for bone remodelling in 
bone loss and arthritis (Figure 2) (Choi et al. 2011; Park 
et al. 2009). Jimi et al. (2004) demonstrated that bone 
destruction and inflammation are closely linked in diseases 
via inhibition of NF-κB lead to block osteogenesis and 
prevent inflammatory bone destruction in vivo. Similar 
results with several studies done by Coon et al. (2007), 
Han et al. (2007), Mino et al. (1998) and Teitelbaum and 
Ross (2003), showed that the osteoclast development, 
involvement of inflammatory cytokines and the signalling 
pathway of RANKL are important in bone remodelling.
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 Osteoclast  differentiat ion from monocyte/
macrophage precursor cells is controlled by two currently 
known factors, macrophage colony-stimulation factor 
(M-CSF) and receptor activator of nuclear factor κB 
(NF-κB) ligand (RANKL) (Theill et al. 2002; Zhao et al. 
2007). M-CSF and RANKL are two important cytokines 
that involved in osteoclastogenesis (Theill et al. 2002). 
The osteoblasts will secrete M-CSF to provide the survival 
of precursor cell signaling (Yoshida et al. 1990). RANKL 
binding to its receptor RANK activates TNF receptor-
associated factor 6 (TRAF6), which is linked to NF-κB and 
mitogen-activated protein kinases (MAPKs) (Kobayashi et 
al. 2001; Lee et al. 2002). In addition, RANKL induces the 
key transcription factor for osteoclastogenesis, nuclear 
factor of activated T cell c1 (NFATc1) (Takayanagi et al. 
2002).
 In year 2005, Luo et al. showed that osteoblast 
lineage cells expressed a membrane bound form of RANKL 
after treatment with Ficus carica extract in vitro. The 
osteoblast precursor cell lineage, express a membrane 
bound form of RANKL, a member of the tumor necrosis 
factor (TNF) cytokine family and strongly activates the 
NF-κB pathway. Study done by Takayanagi et al. (2002) 
and Yamashita et al. (2007) reported that the binding 
of RANKL to its receptor RANK in bone marrow-derived 
macrophages (BMMs) recruits TNF receptor-associated 
factor 1 (TRAF) family proteins such as TRAF6, which play 
roles in interaction with NF-κB and c-Jun NH2-terminal 
kinases (JNK) pathways.
 The canonical NF-κB pathway involves the 
phosphorylation of the IkappaB kinase (IκB) kinase 
complex inhibitor caused by the ligation of RANK (Luo 
et al. 2005). Phosphorylation of NF-κB associated IκB 
leads to its ubiquitination and proteosomal degradation. 
IκB is an enzyme complex that play role in propagating 
the cellular response to inflammation (Viatour et al. 
2005). The transcription factor Nuclear factor of activated 
T- cells, cytoplasmic 1 (NFATc1), Tartrate-resistant 
acid phosphatase (TRAP), cathepsin K and Matrix 
metallopeptidase 9 (MMP-9), also plays a critical role 
in RANKL-induced osteoclastogenesis (Motyckova et al. 
2001; Takayanagi et al. 2002). AP-1 and NF-κB binding 
sites were reported to be present within the promoter 
region of the NFATc1 gene, explaining the connection 
between NFATc1 and NF-κB (Zhou et al. 2002).
 During osteoblast differentiation in bone remodelling, 
BMP-2 enhances osteoclast differentiation by upregulating 
the RANKL (Tachi et al. 2010). BMP-2, which belongs 
FIGURE 2. Schematic diagram destruction of bone remodelling process in osteoporosis, 
involving RANKL/RANK pathway
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to the transforming growth factor-β (TGF-β) super 
family, transduces its signal to the target bone genes 
such as alkaline phosphatase (ALP), bone sialoprotein, 
osteocalcin, Runt-related transcription factor 2 (RUNX2) 
and distal-less homeobox 5 (Dlx5) (Mukherjee et al. 2010; 
Tachi et al. 2010).
 In this review we discussed that the E-DHA was found 
to be a much more potent inhibitor of osteoclastogenesis 
in RANKL-induced RAW264.7 cells than DHA, cis-11, 14- 
eicosadienoic acid or EPA done by Choi et al. (2011). 
Moreover, the E-DHA may exert its inhibitory effect by 
suppressing the JNK and NF-κB signalling pathways 
which correlated with the MMP-9, c-fms and TRAP 
expression. Interestingly, Choi et al. (2011) reported 
that the DHA strongly induced osteoblast differentiation 
in MC3T3-E1 and these results supported that a DHA 
diet induces bone formation but does not inhibit bone 
resorption in animal experiments. In vitro study done 
by Rahman et al. (2008) also reported that the effects 
of mixed fatty acid supplements with different DHA 
contents on bone mass by inhibition the RANKL- induced 
differentiation of osteoclasts from RAW264.7 cells after 
DHA treatment.
 However in vivo study done by Poulsen et al. 
(2007), reported the inhibitory effects of DHA on mature 
osteoclasts might be minimal or transient because no 
effect of DHA on bone resorption was observed in growing 
male rats or in ovariectomized (OVX) female rats. They 
also reported a significantly increase in bone formation 
or a change in the site of bone formation.
 Park et al. (2009) reported that HF6-FC inhibited 
NF-κB transcriptional activity, phosphorylation of 
IκB and p65. The involvement of these transcription 
factor and kinases in RANKL induced osteogenesis is 
well established. RANKL has been reported to activates 
extracellular signal-regulated kinases (ERK), JNK 
and Mitogen-Activated Protein Kinase p38 (p38) in 
osteoclasts and their precursor cells in NF-κB pathways 
(Chang et al. 2007; Kobayashi et al. 2001; Lee et al. 2002; 
Yoshida et al. 1990). However, study done by Miyazaki et 
al. (2000) reported that in osteoclasts differentiation, ERK 
activity correlates with cell survival through the activation 
of c-Fos, JNK increases AP-1 transcriptional activity via 
c-Jun phosphorylation, but not with resorption function.
 Interestingly, they also showed that HF6-FC inhibited 
the RANKL-induced p38 kinase activation, but HF6-FC 
did not inhibit the ERK activation. Moreover, they showed 
that the HF6-FC prolonged ERK activity, suggesting the 
pivotal role of HF6-FC in influencing osteoclast survival 
through ERK, while inhibiting osteoclastogenesis via p38 
kinase. Accordingly, they reported that HF6-FC did not 
affect the expression of MMP9, TRAP, RANK and cathepsin 
K in RANKL-induced RAW 264.7 cells.
STRENGTHS AND LIMITATIONS
General positive outcomes were reported in all studies 
included. Availability of evidence in the literature specific 
to the application of fig on bone health is limited. Different 
parts of the Ficus plant were used by investigators of each 
study included in the review making the interpretation of 
its efficacy difficult.
IMPLICATIONS FOR FUTURE RESEARCH
In order to make strong conclusions about the claimed 
benefits of fig on promotion bone health, further studies 
could help to define the minimum effective dose of fig 
required for beneficial effects, the minimum effective 
duration of consumption or supplementation, as well as the 
best preparation of extract for maximal beneficial effect. 
However, given that the evidence to date does support 
some impact of fig on bone health.
IMPLICATIONS FOR CLINICAL APPLICATION
The impact in in vivo study is unknown. If there is proven 
beneficial effect of fig on bone health, more work has 
to be initiated in order to make Ficus carica as a useful 
supplement as well as treatment for bone diseases. 
Nevertheless, before this could be planned, concurrently 
the adverse effects of fig extract must be clearly evaluated.
CONCLUSION
This study showed that Ficus carica has beneficial 
effects on bone health due to its high minerals content 
and inhibition of osteoclastogenesis via RANKL pathway. 
Therefore, Ficus carica has a potential to be used as a 
pharmaceutical product for bone health.
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